CXCL10 and neoplasm: In addition to mollifying the tumor-induced suppression of T-cell activity, immune checkpoint blockade with anti-PD-1 therapy augments lymphocyte trafficking in tumor-bearing mice by promoting the elaboration of the lymphocyte-attracting cytokines interferon-γ (IFN-γ) and CXCL10 (105).